Effects of antiarrhythmic medication on implantable cardioverter- defibrillator function

American Journal of Cardiology

Volumn 85, Issue 12, 2000, Pages 1481-1485

  Page, Richard L ^a  

^a Texas Cardiac Arrhythmia   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; DOFETILIDE; FLECAINIDE; LIDOCAINE; MEXILETINE; PROPAFENONE; SOTALOL;

CLINICAL TRIAL; DEFIBRILLATION; DEFIBRILLATOR; HEART VENTRICLE ARRHYTHMIA; HUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 0034659643     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(00)00799-2     Document Type: Note

References (34)

1. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 337:1997;1576-1583.
2. Ferguson J.J. Meeting highlights 47th annual Scientific Sessions of the American College of Cardiology . Circulation. 97:1998;2377-2381.
3. Moss A.J., Hall W.J., Cannom D.S., Daubert J.P., Higgins S.L., Klein H., Levine J.H., Saksena S., Waldo A.L., Wilber D., Brown M.W., Heo M. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 335:1996;1933-1940.
4. Buxton A.E., Lee K.L., Fisher J.D., Josephson M.E., Prystowsky E.N., Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med. 341:1999;1882-1890.
5. Klein H., Auricchio A., Reek S., Geller C. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction SCD-HEFT and MADIT-II . Am J Cardiol. 83:1999;91D-97D.
6. Greene H.L. Interactions between pharmacologic and nonpharmacologic antiarrhythmic therapy. Am J Card. 78:1996;61-66.
7. Horton R.P., Canby R.C., Román C.A., Hull M.L., Kaye S.A., Jessen M.E., Page R.L. Determinants of nonthoracotomy biphasic defibrillation. PACE. 20:(Part I):1997;60-64.
8. Reiffel J.A., Coromilas J., Zimmerman J.M., Spotnitz H.M. Drug-device interactions clinical considerations . PACE. 8:1985;369-373.
9. Stevens S.K., Haffaje C.I., Naccarelli G.V., Schwartz K.M., Luceri R.M., Packer D.L., Rubin A.M., Kowey P.R. Effects of oral propafenone on defibrillation and pacing thresholds in patients receiving implantable cardioverter-defibrillators. J Am Coll Cardiol. 28:1996;418-422.
10. Babbs C.F., Yim G.K.W., Whistler S.J., Tacker W.A., Geddes L.A. Elevation of ventricular defibrillation threshold in dogs by antiarrhythmic drugs. Am Heart J. 98:1979;345-350.
11. Marinchak R.A., Friehling T.D., Kline R.A., Stohler J., Kowey P.R. Effect of antiarrhythmic drugs on defibrillation threshold case report of an adverse effect of mexiletine and review of the literature . PACE. 11:1988;7-12.
12. Dorian P., Fain E.S., Davy J., Winkle R.A. Effect of quinidine and bretylium on defibrillation energy requirements. Am Heart J. 112:1986;19-25.
13. Echt D.S., Black J.N., Barbey J.T., Coxe D.R., Cato E. Evaluation of antiarrhythmic drugs on defibrillation energy requirements in dogs sodium channel block and action potential prolongation . Circulation. 79:1989;1106-1117.
14. Murakawa Y., Inoue H., Kuo T., Sezaki K., Nakajima T., Usui M., Yamashita T., Ajiki K., Oikawa N., Sugimoto T., Omata M. Prolongation of intraventricular conduction time associated with fatal impairment of defibrillation efficiency during treatment with class I antiarrhythmic agents. J Cardiovasc Pharmacol. 25:1995;194-199.
15. Echt D.S., Gremillion S.T., Lee J.T., Roden D.M., Murray K.T., Borganelli M., Crawford D.M., Stewart J.R., Hammon J.W. Effects of procainamide and lidocaine on defibrillation energy requirements in patients receiving implantable cardioverter defibrillator devices. J Cardiovasc Electrophysiol. 5:1994;752-760.
16. Kerber R.E., Pandian N.G., Jensen S.R., Constantin L., Kieso R.A., Melton J., Hunt M. Effect of lidocaine and bretylium on energy requirements for transthoracic defibrillation experimental studies . J Am Coll Cardiol. 7:1986;397-405.
17. Murakawa Y., Yamashita T., Kanese Y., Omata M. Do the effects of antiarrhythmic drugs on defibrillation efficacy vary among different shock waveforms? PACE. 21:1998;1901-1908.
18. Ujhelyi M.R., Schur M., Frede T., Gabel M., Markel M.L. Differential effects of lidocaine on defibrillation threshold with monophasic versus biphasic shock waveforms. Circulation. 92:1995;1644-1650.
19. Jung W., Manz M., Pizzulli L., Pfeiffer D., Luderitz B. Effects of chronic amiodarone therapy on defibrillation threshold. Am J Cardiol. 70:1992;1023-1027.
20. Hernandez R., Mann D.E., Breckinridge S., Williams G.R., Reiter M.J. Effects of flecainide on defibrillation thresholds in the anesthetized dog. J Am Coll Cardiol. 14:1989;777-781.
21. Pharand C., Goldman R., Fan C., Chow M., Kluger J. Effect of chronic oral moricizine and intravenous epinephrine on ventricular fibrillation and defibrillation thresholds. PACE. 19:1996;82-89.
22. Wang M., Dorian P. DL and D sotalol decrease defibrillation energy requirements. PACE. 12:1989;1522-1529.
23. Dorian P., Newman D. Effect of sotalol on ventricular fibrillation and defibrillation in humans. Am J Cardiol. 72:1993;72A-79A.
24. Dorian P., Newman D., Sheahan R., Tang A., Green M., Mitchell J. d-Sotalol decreases defibrillation energy requirements in humans a novel indication for drug therapy . J Cardiovasc Electrophysiol. 7:1996;952-961.
25. Frame L.H. The effect of chronic oral and acute intravenous amiodarone administration on ventricular defibrillation threshold using implanted electrodes in dogs. PACE. 12:1989;339-346.
26. Troup P.J., Chapman P.D., Olinger G.N., Kleinman L.H. The implanted defibrillator relation of defibrillating lead configuration and clinical variables to defibrillation threshold . J Am Coll Cardiol. 6:1985;1315-1321.
27. Raitt M.H., Johnson G., Dolack G.L., Poole J.E., Kudenchuk P.J., Bardy G.H. Clinical predictors of the defibrillation threshold with the unipolar implantable defibrillation system. J Am Coll Cardiol. 25:1995;1576-1583.
28. Kuo W.H., Kirsh M.M., Bolling S.F., Stirling M., Kadish A.H., DeBuitleir M., Calkins H., Lewis R.R., Morady F. Effect of antiarrhythmic drug therapy on the incidence of shocks in patients who receive an implantable cardioverter defibrillator after a single episode of sustained ventricular tachycardia/fibrillation. PACE. 14:1991;1586-1592.
29. Huang S.K.S., de Guzman W.L.T., Chenarides J.G., Okike N.O., Vander Salm T.J. Effects of long-term amiodarone therapy on the defibrillation threshold and the rate of shocks of the implantable cardioverter-defibrillator. Am Heart J. 122:1991;720-727.
30. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). Am J Cardiol. 72:1993;280-287.
31. Pacifico A., Hohnloser S.H., Williams J.H., Tao B., Saksena S., Henry P.D., Prystowsky E.N. Prevention of implantable-defibrillator shocks by treatment with sotalol. N Engl J Med. 340:1999;1855-1862.
32. O'Toole M, O'Neill G, Kluger J, Bonney SL, Billing CB, Friedrich T. Efficacy and safety of oral dofetilide in patients with an implanted defibrillator: a multicenter study. (abstr). Circulation 1999;100:I-794.
33. Dougherty C.M. Psychological reactions and family adjustment in shock versus no shock groups after implantation of internal cardioverter defibrillator. Heart Lung. 24:1995;281-291.
34. Exner D.V., Schron E.B., Yao Q., Vloka M.E., Page R.L., Powell J., Steinberg J.S. Defibrillator shocks and self-perceived quality of life in the antiarrhythmics versus implantable defibrillators (AVID) trial. (abstr) J Am Coll Cardiol. 35:2000;153A.